Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,790 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.
Noshi T, Kitano M, Taniguchi K, Yamamoto A, Omoto S, Baba K, Hashimoto T, Ishida K, Kushima Y, Hattori K, Kawai M, Yoshida R, Kobayashi M, Yoshinaga T, Sato A, Okamatsu M, Sakoda Y, Kida H, Shishido T, Naito A. Noshi T, et al. Among authors: hattori k. Antiviral Res. 2018 Dec;160:109-117. doi: 10.1016/j.antiviral.2018.10.008. Epub 2018 Oct 11. Antiviral Res. 2018. PMID: 30316915 Free article.
Discovery of novel 5-hydroxy-4-pyridone-3-carboxy acids as potent inhibitors of influenza Cap-dependent endonuclease.
Miyagawa M, Akiyama T, Mikamiyama-Iwata M, Hattori K, Kurihara N, Taoda Y, Takahashi-Kageyama C, Kurose N, Mikamiyama H, Suzuki N, Takaya K, Tomita K, Matsuo K, Morimoto K, Yoshida R, Shishido T, Yoshinaga T, Sato A, Kawai M. Miyagawa M, et al. Among authors: hattori k. Bioorg Med Chem Lett. 2016 Oct 1;26(19):4739-4742. doi: 10.1016/j.bmcl.2016.08.038. Epub 2016 Aug 18. Bioorg Med Chem Lett. 2016. PMID: 27568084
Discovery of (-)-6-[2-[4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]-1-hydroxyethyl]-3,4-dihydro-2(1H)-quinolinone--a potent NR2B-selective N-methyl D-aspartate (NMDA) antagonist for the treatment of pain.
Kawai M, Ando K, Matsumoto Y, Sakurada I, Hirota M, Nakamura H, Ohta A, Sudo M, Hattori K, Takashima T, Hizue M, Watanabe S, Fujita I, Mizutani M, Kawamura M. Kawai M, et al. Among authors: hattori k. Bioorg Med Chem Lett. 2007 Oct 15;17(20):5558-62. doi: 10.1016/j.bmcl.2007.08.014. Epub 2007 Aug 15. Bioorg Med Chem Lett. 2007. PMID: 17766106
Discovery of novel and orally active NR2B-selective N-methyl-D-aspartate (NMDA) antagonists, pyridinol derivatives with reduced HERG binding affinity.
Kawai M, Nakamura H, Sakurada I, Shimokawa H, Tanaka H, Matsumizu M, Ando K, Hattori K, Ohta A, Nukui S, Omura A, Kawamura M. Kawai M, et al. Among authors: hattori k. Bioorg Med Chem Lett. 2007 Oct 15;17(20):5533-6. doi: 10.1016/j.bmcl.2007.08.039. Epub 2007 Aug 22. Bioorg Med Chem Lett. 2007. PMID: 17768047
Structure-activity relationship study of novel NR2B-selective antagonists with arylamides to avoid reactive metabolites formation.
Kawai M, Sakurada I, Morita A, Iwamuro Y, Ando K, Omura H, Sakakibara S, Masuda T, Koike H, Honma T, Hattori K, Takashima T, Mizuno K, Mizutani M, Kawamura M. Kawai M, et al. Among authors: hattori k. Bioorg Med Chem Lett. 2007 Oct 15;17(20):5537-42. doi: 10.1016/j.bmcl.2007.08.033. Epub 2007 Aug 19. Bioorg Med Chem Lett. 2007. PMID: 17766107
Synthesis and structure-activity relationships of oxamyl dipeptide caspase inhibitors developed for the treatment of liver disease.
Ueno H, Kawai M, Shimokawa H, Hirota M, Ohmi M, Sudo R, Ohta A, Arano Y, Hattori K, Ohmi T, Kato N, Kojima M, Ueno Y, Yamamoto M, Moriguchi Y, Eda H, Masubuchi K. Ueno H, et al. Among authors: hattori k. Bioorg Med Chem Lett. 2009 Jan 1;19(1):199-202. doi: 10.1016/j.bmcl.2008.10.117. Epub 2008 Nov 5. Bioorg Med Chem Lett. 2009. PMID: 19013793
1,790 results